WO2023088375A1 - β-内酰胺酶抑制剂中间体及制备方法 - Google Patents
β-内酰胺酶抑制剂中间体及制备方法 Download PDFInfo
- Publication number
- WO2023088375A1 WO2023088375A1 PCT/CN2022/132591 CN2022132591W WO2023088375A1 WO 2023088375 A1 WO2023088375 A1 WO 2023088375A1 CN 2022132591 W CN2022132591 W CN 2022132591W WO 2023088375 A1 WO2023088375 A1 WO 2023088375A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- solvent
- compound shown
- reaction
- compound
- Prior art date
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title claims abstract description 14
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title claims abstract description 14
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 114
- 239000002904 solvent Substances 0.000 claims abstract description 324
- 150000001875 compounds Chemical class 0.000 claims abstract description 298
- 238000006243 chemical reaction Methods 0.000 claims abstract description 247
- -1 oxadiazazole compound Chemical class 0.000 claims abstract description 162
- 238000000034 method Methods 0.000 claims abstract description 82
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 56
- 230000002378 acidificating effect Effects 0.000 claims abstract description 12
- 238000003419 tautomerization reaction Methods 0.000 claims abstract description 12
- 239000012024 dehydrating agents Substances 0.000 claims abstract description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 159
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 150
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 109
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 93
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 73
- 229910052757 nitrogen Inorganic materials 0.000 claims description 73
- 239000002585 base Substances 0.000 claims description 70
- 239000000243 solution Substances 0.000 claims description 66
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 57
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 46
- 150000008282 halocarbons Chemical class 0.000 claims description 43
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 38
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 36
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 36
- 239000011261 inert gas Substances 0.000 claims description 32
- 239000003960 organic solvent Substances 0.000 claims description 32
- 238000007112 amidation reaction Methods 0.000 claims description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 229910052786 argon Inorganic materials 0.000 claims description 27
- 239000003513 alkali Substances 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 24
- 150000002825 nitriles Chemical class 0.000 claims description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 22
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 22
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 22
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
- 239000004210 ether based solvent Substances 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 17
- 229910052783 alkali metal Inorganic materials 0.000 claims description 17
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 17
- 239000003054 catalyst Substances 0.000 claims description 17
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 17
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 16
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 14
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 14
- 239000012973 diazabicyclooctane Substances 0.000 claims description 14
- 239000003444 phase transfer catalyst Substances 0.000 claims description 14
- 238000007142 ring opening reaction Methods 0.000 claims description 14
- 239000002262 Schiff base Substances 0.000 claims description 13
- 150000004753 Schiff bases Chemical class 0.000 claims description 13
- 239000003849 aromatic solvent Substances 0.000 claims description 13
- 238000006480 benzoylation reaction Methods 0.000 claims description 13
- 239000003759 ester based solvent Substances 0.000 claims description 13
- 239000003446 ligand Substances 0.000 claims description 13
- UOKZUTXLHRTLFH-UHFFFAOYSA-N o-phenylhydroxylamine Chemical compound NOC1=CC=CC=C1 UOKZUTXLHRTLFH-UHFFFAOYSA-N 0.000 claims description 13
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims description 12
- 238000006677 Appel reaction Methods 0.000 claims description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 12
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 12
- 230000009435 amidation Effects 0.000 claims description 12
- 229920002866 paraformaldehyde Polymers 0.000 claims description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 12
- 235000011181 potassium carbonates Nutrition 0.000 claims description 12
- 238000006722 reduction reaction Methods 0.000 claims description 12
- 150000001340 alkali metals Chemical class 0.000 claims description 10
- 150000001408 amides Chemical group 0.000 claims description 10
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 10
- 150000007530 organic bases Chemical class 0.000 claims description 10
- 150000004866 oxadiazoles Chemical class 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 238000005917 acylation reaction Methods 0.000 claims description 9
- 239000003638 chemical reducing agent Substances 0.000 claims description 9
- 238000006264 debenzylation reaction Methods 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 238000006277 sulfonation reaction Methods 0.000 claims description 9
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 8
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 8
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical group CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- 229910052763 palladium Inorganic materials 0.000 claims description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 239000008098 formaldehyde solution Substances 0.000 claims description 7
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 7
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 7
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 7
- VEPTXBCIDSFGBF-UHFFFAOYSA-M tetrabutylazanium;fluoride;trihydrate Chemical compound O.O.O.[F-].CCCC[N+](CCCC)(CCCC)CCCC VEPTXBCIDSFGBF-UHFFFAOYSA-M 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical group OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 6
- 150000002466 imines Chemical class 0.000 claims description 6
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 6
- 230000001035 methylating effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 6
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 claims description 5
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 5
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 5
- 239000011736 potassium bicarbonate Substances 0.000 claims description 5
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 239000012279 sodium borohydride Substances 0.000 claims description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
- 150000004030 azacyclic compounds Chemical class 0.000 claims description 4
- 150000003851 azoles Chemical class 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 4
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical group BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical group [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 4
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 claims description 4
- 239000005456 alcohol based solvent Substances 0.000 claims description 3
- 150000001923 cyclic compounds Chemical class 0.000 claims description 3
- 230000009615 deamination Effects 0.000 claims description 3
- 238000006481 deamination reaction Methods 0.000 claims description 3
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 claims description 3
- 150000002357 guanidines Chemical class 0.000 claims description 3
- 150000002429 hydrazines Chemical class 0.000 claims description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 3
- 239000005453 ketone based solvent Substances 0.000 claims description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 3
- 239000012022 methylating agents Substances 0.000 claims description 3
- JNUZADQZHYFJGW-JOCHJYFZSA-N (2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide Chemical compound FC=1C(=NC(=NC=1)NC1=C(C(=CC=C1)S(=O)(=O)C)F)C1=CNC2=C(C=CC=C12)NC([C@@H](COC)N1CCN(CC1)C)=O JNUZADQZHYFJGW-JOCHJYFZSA-N 0.000 claims description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 claims description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims description 2
- ORBBTCHHNMWMCP-UHFFFAOYSA-K cycloocta-1,5-diene trichloroiridium Chemical class [Ir](Cl)(Cl)Cl.C1=CCCC=CCC1 ORBBTCHHNMWMCP-UHFFFAOYSA-K 0.000 claims description 2
- 229940043279 diisopropylamine Drugs 0.000 claims description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000002462 imidazolines Chemical class 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 claims description 2
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 claims description 2
- YYHPEVZFVMVUNJ-UHFFFAOYSA-N n,n-diethylethanamine;sulfur trioxide Chemical compound O=S(=O)=O.CCN(CC)CC YYHPEVZFVMVUNJ-UHFFFAOYSA-N 0.000 claims description 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical compound CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 2
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 claims description 2
- PBDBXAQKXCXZCJ-UHFFFAOYSA-L palladium(2+);2,2,2-trifluoroacetate Chemical compound [Pd+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F PBDBXAQKXCXZCJ-UHFFFAOYSA-L 0.000 claims description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 claims description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 claims description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical group 0.000 claims description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 6
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims 1
- FVHVJARLLUJUTI-UHFFFAOYSA-N 2-cyclooctylazocane Chemical class C1CCCCCCC1C1NCCCCCC1 FVHVJARLLUJUTI-UHFFFAOYSA-N 0.000 claims 1
- KTYAQHYBYRVCGD-UHFFFAOYSA-N [Ir].COC1=CC=CCCCC1 Chemical class [Ir].COC1=CC=CCCCC1 KTYAQHYBYRVCGD-UHFFFAOYSA-N 0.000 claims 1
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical class C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 claims 1
- 150000002443 hydroxylamines Chemical class 0.000 claims 1
- 238000009776 industrial production Methods 0.000 abstract description 3
- 239000012074 organic phase Substances 0.000 description 81
- 238000003756 stirring Methods 0.000 description 55
- 239000012141 concentrate Substances 0.000 description 54
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 46
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 45
- 239000000047 product Substances 0.000 description 30
- 239000012065 filter cake Substances 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 19
- 238000012544 monitoring process Methods 0.000 description 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 19
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 18
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 239000002132 β-lactam antibiotic Substances 0.000 description 16
- 229940124586 β-lactam antibiotics Drugs 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 238000005070 sampling Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 239000012071 phase Substances 0.000 description 12
- 239000011701 zinc Substances 0.000 description 12
- 239000011734 sodium Substances 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 235000019270 ammonium chloride Nutrition 0.000 description 9
- 102000006635 beta-lactamase Human genes 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 8
- 238000010791 quenching Methods 0.000 description 7
- 238000013517 stratification Methods 0.000 description 7
- 108090000204 Dipeptidase 1 Proteins 0.000 description 6
- 239000005909 Kieselgur Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 108020004256 Beta-lactamase Proteins 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- 239000007821 HATU Substances 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical class C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 description 1
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical group CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- VFBGUPNPSJRPIF-UHFFFAOYSA-N 1-methoxycycloocta-1,3-diene Chemical compound COC1=CC=CCCCC1 VFBGUPNPSJRPIF-UHFFFAOYSA-N 0.000 description 1
- MGGVALXERJRIRO-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-2-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-1H-pyrazol-5-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)O MGGVALXERJRIRO-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- XWURZHGKODQZMK-UHFFFAOYSA-N O.[Ru]=O Chemical compound O.[Ru]=O XWURZHGKODQZMK-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SMOBCLHAZXOKDQ-ZJUUUORDSA-N [(2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound O=C([C@H]1N2C[C@@](CC1)(N(C2=O)OS(O)(=O)=O)[H])NC1CCNCC1 SMOBCLHAZXOKDQ-ZJUUUORDSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- NDCUAPJVLWFHHB-UHNVWZDZSA-N avibactam Chemical compound C1N2[C@H](C(N)=O)CC[C@@]1([H])N(OS(O)(=O)=O)C2=O NDCUAPJVLWFHHB-UHNVWZDZSA-N 0.000 description 1
- 229960002379 avibactam Drugs 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical class C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- GUTPQYNJVRSYHY-UHFFFAOYSA-N ethyl acetate;sulfuric acid Chemical compound OS(O)(=O)=O.CCOC(C)=O GUTPQYNJVRSYHY-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002503 iridium Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- DBTXKJJSFWZJNS-UHFFFAOYSA-N o-phenylhydroxylamine;hydrochloride Chemical compound Cl.NOC1=CC=CC=C1 DBTXKJJSFWZJNS-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical class C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229950011310 relebactam Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 1
- 229960003865 tazobactam Drugs 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Definitions
- the invention relates to a beta-lactamase inhibitor intermediate and a preparation method.
- ⁇ -lactam antibiotics were the first antibiotics to be used clinically. Since penicillin G was successfully applied clinically as the first ⁇ -lactam antibiotic, ⁇ -lactam antibiotics have been developed rapidly. Different structural types of ⁇ -lactam antibiotics have been developed and widely used clinically with good results. However, because bacterial cells can produce ⁇ -lactamase, which inactivates antibiotics, bacteria develop resistance to ⁇ -lactam antibiotics. ⁇ -lactamases are enzymes that catalyze the hydrolysis of ⁇ -lactam rings, which inactivate the antibacterial activity of ⁇ -lactam antibiotics and allow bacterial resistance to ⁇ -lactam antibiotics.
- ⁇ -lactamases can be divided into class A, class B, class C and class D according to the difference in amino acid sequence in the molecular structure.
- Class A ⁇ -lactamases preferentially hydrolyze penicillin antibiotics
- Class B ⁇ -lactams can hydrolyze various ⁇ -lactam antibiotics, including carbapenems
- Class C ⁇ -lactams are more effective Hydrolyze cephalosporin antibiotics
- D-lactamases are more inclined to hydrolyze oxacillin and cloxacillin.
- the resistance of bacteria, especially Gram-negative bacteria, to ⁇ -lactam antibiotics is usually mediated by ⁇ -lactamase.
- Inhibition of ⁇ -lactamase can delay or inhibit the degradation of ⁇ -lactam antibiotics and restore the sensitivity of ⁇ -lactam antibiotic-resistant bacteria to ⁇ -lactam antibiotics.
- the combined application of ⁇ -lactamase and ⁇ -lactam antibiotics can inactivate the hydrolysis activity of ⁇ -lactamase for ⁇ -lactam antibiotics, thereby enhancing the bacterial resistance to ⁇ -lactams.
- Antibiotic susceptibility reducing or overcoming the problem of drug resistance.
- the prior art discloses a variety of bacterial ⁇ -lactamase inhibitors, such as WO2013149121A1, WO2014141132A1, US20130296290A1, WO2013030735A1, WO2015110963A1, WO2015150890A1, WO2015159265A1, WO201517 3663, WO2015173665A1, WO2017055922A1 disclosed diazaspiro[bicyclo[3.2.1 ] Octane compounds.
- ⁇ -lactamase inhibitors on the market, such as clavulanic acid, tazobactam, avibactam, Relebactam, etc.
- Patent application WO2019144912A1 discloses a ⁇ -lactamase inhibitor represented by the following formula I, which has better antibacterial activity.
- the first step uses condensing agent HATU etc. to condense, but the cost of HATU condensing agent is very high and is only suitable for small samples; (2) SM-6 and SM-7 are unstable in acidic systems; (3) from raw materials SM-1 starts with a total of 9 steps of reaction.
- the original preparation method has a long reaction route and harsh reaction conditions, is not suitable for large-scale industrial production, and the yield needs to be further improved.
- the technical problem to be solved by the present invention is to overcome the existence of lengthy synthetic route, low total yield, use of toxic, harmful, dangerous or expensive reagents, harsh reaction conditions and (or)
- the technical defects such as poor repeatability and scalability of the reaction are not suitable for large-scale synthesis, so the ⁇ -lactamase inhibitor intermediate, preparation method, and intermediate are provided.
- the preparation method provided by the invention has cheap and easy-to-obtain starting materials, avoids toxic, harmful and (or) dangerous reagents and harsh reaction conditions, significantly shortens the number of reaction steps, and significantly improves the total yield.
- the reproducibility and scalability are significantly improved, making it more suitable for industrial synthesis.
- the present invention solves the above-mentioned technical problems through the following technical solutions.
- the present invention provides a method for preparing a diazabicyclooctane compound as shown in Formula 8, which comprises the following steps: adding a mixture of triphosgene and a solvent to the compound shown in Formula 7 and/or its In the mixture of salt, alkali and solvent, carry out amidation ring closure reaction as shown below, obtain the diazabicyclooctane compound as shown in formula 8;
- the solvent may be one or more of acetonitrile, halogenated hydrocarbon solvents (such as dichloromethane) and aromatic hydrocarbon solvents (such as toluene).
- the solvent can be used in an amount that does not affect the reaction, for example, the mass percentage of triphosgene in the mixture of triphosgene and solvent can be 10%.
- the volume to mass ratio of the solvent to the compound shown in formula 7 can be 3mL/g.
- the salt of the compound shown in formula 7 can be hydrochloride, for example, 2 equivalents of hydrochloric acid.
- the base can be an organic base, such as N,N-diisopropylethylamine DIPEA and/or triethylamine.
- the mol ratio of described alkali and described compound shown in formula 7 can be 4:1; Or, the mol ratio of described alkali and described compound shown in formula 7 can be 6: 1.
- the molar ratio of the triphosgene to the compound represented by formula 7 and/or its salt may be 0.35:1 to 0.5:1; for example, 0.38:1 to 0.4:1.
- the temperature of the indicated amidation ring-closing reaction may be from -10°C to 0°C.
- the amidation ring-closing reaction is preferably carried out under inert gas, such as nitrogen and argon.
- the preparation method can be the following steps: after adding the base to the mixture of the compound shown in formula 7 and/or its salt and solvent at an internal temperature of 10°C to 30°C, adding 10% Sanguang Gas and solvent solution, carry out amidation ring closure reaction as shown, obtain the diazabicyclooctane compound as shown in formula 8.
- the progress of the amidation ring-closing reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR). Generally, when the compound shown in formula 7 disappears or no longer reacts, it is used as the end point of the reaction.
- the time for the amidation ring-closing reaction is preferably 8 hours-15 hours, such as 9-10 hours.
- Post-treatment may also be included in the step; the post-treatment may include the following steps: after the amidation reaction is completed, add water and methyl tert-butyl ether to mix, wash and separate the organic phase obtained, and concentrate the organic phase , add acetone to concentrate.
- the quenching can be controlled by adding 5 times the mass ratio of water and 7 times the mass ratio of methyl tert-butyl ether of the compound shown in formula 7 at 15 to 25 ° C;
- the washing can be A mixed aqueous solution of 5% sodium carbonate and 5% sodium chloride of 8 times the mass ratio of the compound shown in Formula 7 and a saturated aqueous sodium chloride solution of 5 times the mass ratio were added successively for washing.
- the concentration can be controlled under reduced pressure at a temperature not higher than 55°C.
- the solvent may be an ester solvent, such as ethyl acetate.
- the solvent can be used in an amount that does not affect the reaction, for example, the volume-to-mass ratio of the solvent to the compound shown in formula 6 can be 9mL/g-15mL/g, for example 12mL/g.
- the molar ratio of the sulfuric acid to the compound 6 may be 4:1 to 12:1; for example, 12:1.
- the sulfuric acid can be added in the form of a solution of concentrated sulfuric acid and the solvent; in the solution, the mass ratio of the concentrated sulfuric acid to the solvent can be 1.4:1.
- the reaction temperature of step (1) may be -45°C to -5°C, for example -35°C to -25°C.
- the reaction progress of step (1) can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and generally the end point of the reaction is when the compound shown in formula 6 disappears or no longer reacts.
- the reaction time is preferably 10 hours to 30 hours, for example 21 hours.
- step (1) After the reaction in step (1) is completed, it can be directly used in step (2) for the reduction reaction to prepare the compound 7 without post-treatment.
- the reducing agent can be sodium borohydride, borane methyl sulfide, lithium triethyl borohydride; for example sodium borohydride.
- the molar ratio of the reducing agent to the compound represented by formula 6 may be 4:1 to 6:1; for example, 4:1.
- the temperature of the reduction reaction may be -70°C to -35°C, for example -70°C to -60°C.
- the progress of the reduction reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and generally the end point of the reaction is when the compound shown in formula 7 no longer increases.
- the time for the reduction reaction is preferably 2 hours to 10 hours, for example 4 hours.
- Post-treatment may also be included in the step (2); the post-treatment may include the following steps: after the reduction reaction is finished, add water to quench the reaction, add ammonia water to neutralize the reaction, concentrate the separated organic phase, add Concentrate with ethanol to obtain the compound 7;
- the quenching temperature can be from 0° C. to 10° C.; the concentration of the ammonia water can be 25%; the hydrogen chloride can be ethanol solution of hydrogen chloride, such as 4M ethanol solution of hydrogen chloride.
- the described preparation method may also include the method for preparing the described compound 6, which includes the following steps: in a solvent, in the presence of a base, mix the compound shown in formula 5 with O-phenylhydroxylamine or its Salt is carried out Schiff base reaction, obtains described compound 6 and gets final product;
- the solvent can be an alcohol solvent and/or an ester solvent
- the alcohol solvent can be one or more of ethanol, isopropanol, tert-butanol and tert-amyl alcohol, and the ester
- the quasi-solvent can be ethyl acetate.
- the amount of the solvent may not affect the reaction, for example, the volume-to-mass ratio of the solvent to the compound shown in Formula 5 may be 8mL/g-12mL/g.
- the molar ratio of the compound represented by formula 5 to O-phenylhydroxylamine or a salt thereof may be 1.15:1 to 1.5:1, for example 1.5:1.
- the O-phenylhydroxylamine salt may be its hydrochloride.
- the base may be an alkali metal bicarbonate, such as sodium bicarbonate.
- the molar ratio of the base to the O-phenylhydroxylamine salt may be 2:1.5.
- the molar ratio of the base to the compound represented by formula 5 may be 1.5:1 to 2:1, for example 2:1.
- the Schiff base reaction is preferably carried out under an inert gas such as nitrogen and argon.
- the temperature of the Schiff base reaction may be 15°C to 45°C, for example, 15°C to 25°C.
- the method for preparing the compound 6 comprises the following steps: in a solvent, at 15°C to 25°C, adding the base to the O-phenylhydroxylamine or its salt and To the mixture of solvents, add the mixture of the compound shown in formula 5 and the solvent to carry out the Schiff base reaction to obtain the compound 6.
- the process of the Schiff base reaction can be detected by conventional monitoring methods (such as TLC, HPLC or NMR) in the art, generally as the end point of the reaction when the compound shown in formula 5 disappears or no longer reacts .
- the time for the ring closure reaction is preferably 1 hour to 10 hours, for example 3 hours.
- Post-treatment may also be included in the steps; the post-treatment may include the following steps: after the Schiff base reaction is finished, concentrate, add methyl tert-butyl ether and water for extraction, add citric acid aqueous solution to the organic phase washing. Add sodium bicarbonate solution to the organic phase to wash, concentrate the organic phase, add ethyl acetate and concentrate under reduced pressure to obtain the compound 6.
- Described citric acid aqueous solution can be 10% citric acid aqueous solution, and described washing can be 2 times; Described sodium bicarbonate solution can be 5% sodium bicarbonate solution; Described concentration can be controlled temperature less than 50 °C Concentrate under reduced pressure.
- the described preparation method can also further include the method for preparing the described compound 5, which includes the following steps:
- the solvent can be one or more of aromatic solvents, alcohol solvents, ether solvents, amide solvents and ester solvents;
- the aromatic solvent can be toluene, and the alcohols Solvent can be tert-amyl alcohol and/or pentyl alcohol, described ether solvent can be cyclopentyl methyl ether and/or tetrahydrofuran, described amide solvent can be DMAc and/or DMF, described ester solvent It may be isopropyl acetate; for example toluene.
- the amount of the solvent should not affect the reaction, for example, the volume-to-mass ratio of the solvent to the compound shown in formula 4 can be 2mL/g-3mL/g.
- the catalyst can be bis(triphenylphosphine)cyclopentadienyl ruthenium(II) chloride, 1,5-cyclooctadiene iridium chloride dimer, methoxy(cyclooctadiene)
- iridium dimer copper acetate, cuprous iodide, palladium(II) acetate, trans-bis(acetocyano)palladium(II) dichloride and palladium trifluoroacetate, such as bis(tri Phenylphosphine)cyclopentadienylruthenium(II) chloride.
- the molar ratio of the catalyst to the compound represented by Formula 4 may be 0.01 to 0.1, such as 0.015:1.
- ligands used in this type of reaction in the art can also be added to the ring-closing reaction, and the ligands can be phosphine ligands, such as triphenylphosphine.
- the molar ratio of the ligand to the compound represented by formula 4 may be 0.01 to 0.1, for example 0.04:1.
- the ring-closing reaction is preferably carried out under inert gas, such as nitrogen and argon.
- the temperature of the ring-closing reaction may be from 60°C to 110°C, for example, from 95°C to 105°C.
- the progress of the ring-closing reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and generally the end point of the reaction is when the compound shown in formula 4 disappears or no longer reacts.
- the time for the ring closure reaction is preferably 1 hour to 5 hours, for example 2 hours.
- the steps may also include post-treatment; the post-treatment may include the following steps: after the ring-closing reaction is completed, add water to wash, and concentrate the organic phase.
- the described preparation method can also include the method for preparing the described compound 4, which includes the following steps:
- the solvent can be a mixture of ether solvent and dimethyl sulfoxide
- the ether solvent can be tetrahydrofuran
- the volume ratio of the ether solvent and dimethyl sulfoxide can be 1:1.2 to 3:1, for example 5:3.
- the base may be an alcoholate of an alkali metal, such as potassium tert-butoxide.
- the molar ratio of the base to the compound represented by formula 3 can be a conventional molar ratio for this type of reaction in the art, for example 1:1 to 1.4:1; for example 1.15:1 to 1.2:1.
- the molar ratio of the described trimethylsulfoxide iodide to the compound shown in formula 3 can be the conventional molar ratio of this type of reaction in the art, for example 1:1 to 1.4:1; for example 1.15:1 to 1.2:1.
- the ring-opening reaction is preferably carried out under an inert gas, and the inert gas can be argon or nitrogen.
- the temperature of the ring-opening reaction may be -20-30°C.
- the described step is preferably: after mixing the alkali and trimethylsulfoxide iodide in part of the ether solvent and dimethyl sulfoxide, sequentially add the remaining part of the ether solvent and the formula 3 Shown compound, carry out described ring-opening reaction.
- the mixing temperature may be 20-30°C; the ring-opening reaction temperature may be -10-0°C.
- the progress of the ring-opening reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and generally the end point of the reaction is when the compound shown in formula 3 disappears or no longer reacts.
- the time for the ring-opening reaction is preferably 5 hours to 24 hours, such as 12 hours.
- Post-treatment may also be included in the steps; the post-treatment may include the following steps: after the ring-opening reaction is completed, add an organic solvent and 5% ammonium chloride solution in sequence, separate layers, and use an organic solvent for the water phase After washing, the combined organic phases are washed with 5% to 2% sodium chloride solution, dried, filtered, and the organic phases are concentrated.
- the compound shown in formula 59 is subjected to the following cyclopropylation reaction with a methylating reagent to obtain the compound shown in formula 3. ;
- the solvent may be an amide solvent, such as DMF.
- the solvent can be used in an amount that does not affect the reaction, for example, the volume-to-mass ratio of the solvent to the compound represented by Formula 59 can be 5 mL/g-30 mL/g; for example, 10 mL/g.
- the molar ratio of the Zn/Cu or Zn/Ag reagent to the compound represented by formula 59 may be 0.5:1 to 3:1; for example, 2:1.
- the methylating agent can be dibromomethane and/or diiodomethane.
- the molar ratio of the methylating agent to the compound represented by formula 59 may be 01.5:1 to 3:1; for example, 2:1.
- the cyclopropylation reaction is preferably carried out under an inert gas such as nitrogen and argon.
- the temperature of the cyclopropylation reaction may be 15°C to 45°C, for example, 30°C to 40°C.
- the process of the cyclopropylation reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), generally when the compound shown in formula 59 disappears or no longer reacts as a reaction end.
- the time for the cyclopropylation reaction is preferably 10 hours to 30 hours, such as 17 hours.
- Post-treatment may also be included in the described steps; the post-treatment may include the following steps: after the completion of the cyclopropylation reaction, add ethyl acetate, ammonium chloride aqueous solution (for example 5%) successively, (by diatomaceous earth), separated, washed the aqueous phase with ethyl acetate, washed the combined organic phase with aqueous sodium chloride (eg 5%), concentrated, added methanol and water, precipitated solid, filtered, and dried.
- the preparation method also includes a method for preparing the compound shown in formula 59, which includes the following steps:
- the solvent can be one or more of ether solvents, halogenated hydrocarbon solvents, nitrile solvents, ketone solvents, ester solvents and N,N-dimethylformamide
- the The ether solvent can be tetrahydrofuran and/or 1,4-dioxane
- the halogenated hydrocarbon solvent can be dichloromethane
- the ester solvent can be ethyl acetate
- the nitrile solvent It may be acetonitrile
- the ketone solvent may be acetone; for example, dichloromethane.
- the amount of the solvent should not affect the reaction, for example, the volume-to-mass ratio of the solvent to the compound represented by formula 58 can be 8mL/g-12mL/g.
- the phase transfer catalyst can be a quaternary ammonium salt, such as tetra-n-butylammonium iodide TBAI and/or tetrabutylammonium fluoride trihydrate TBAF.3H 2 O.
- the molar ratio of the phase transfer catalyst to the compound represented by formula 58 may be 0.04:1 ⁇ 0.05:1; for example, 0.045:1.
- Described base can be inorganic base and/or organic base, and described inorganic base can be one or more in alkali metal carbonate, alkali metal bicarbonate and alkali metal alcoholate, and described alkali Metal carbonate can be potassium carbonate and/or cesium carbonate, and described alkali metal bicarbonate can be potassium bicarbonate and/or sodium bicarbonate, and described alkali metal alcoholate can be potassium tert-butoxide, and described
- the organic base can be triethylamine and/or diisopropylamine; for example potassium carbonate.
- the molar ratio of the base to the compound represented by formula 58 may be 2:1 to 3:1.
- the molar ratio of the formaldehyde or paraformaldehyde in the formaldehyde aqueous solution to the compound represented by formula 58 may be 1:1 to 6:1; for example, 3.4:1.
- the alkali and the aqueous formaldehyde solution or paraformaldehyde are added in batches, for example in 3 times on average.
- the reaction is preferably carried out under inert gas, such as nitrogen, argon.
- the reaction temperature may be from 15°C to 55°C, for example, from 35°C to 45°C.
- the progress of the reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and generally the end point of the reaction is when the compound represented by formula 58 disappears or no longer reacts.
- the reaction time is preferably 10 hours to 30 hours, for example 15 hours.
- the steps may also include post-treatment; the post-treatment may include the following steps: after the reaction is completed, add 5% ammonium chloride aqueous solution to quench the reaction, wash the separated organic phase, and concentrate.
- the described preparation method can also include the method for preparing the described compound shown in formula 58, which includes the following steps:
- described solvent can be one or more in ketone solvent, nitrile solvent, ether solvent, ester solvent and halogenated hydrocarbon solvent, and described ketone solvent can be acetone, and described
- the nitrile solvent can be acetonitrile
- the ether solvent can be tetrahydrofuran
- the ester solvent can be ethyl acetate
- the halogenated hydrocarbon solvent can be methylene chloride; for example, tetrahydrofuran.
- the solvent can be used in an amount that does not affect the reaction, for example, the volume-to-mass ratio of the solvent to the compound represented by Formula 57 can be 5 mL/g-10 mL/g.
- the molar ratio of the benzoyl chloride to the compound represented by formula 57 may be from 1.05:1 to 1.1:1.
- the alkali can be an alkali metal alcoholate and/or bis(trimethylsilyl)amide lithium LiHMDS, and the alkali metal alcoholate can be sodium tert-butoxide, lithium tert-butoxide and potassium tert-butoxide one or more of.
- the molar ratio of the base to the compound represented by Formula 57 may be 1.4:1 to 2.5:1.
- the benzoylation reaction is preferably carried out under inert gas, such as nitrogen and argon.
- the temperature of the benzoylation reaction may be -65°C to 25°C, for example -15°C to -5°C.
- the process of the benzoylation reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), generally when the compound shown in formula 57 disappears or no longer reacts as a reaction end.
- the reaction time is preferably 1 hour.
- the method for preparing the compound shown in formula 58 includes the following steps: at -15°C to -5°C, sequentially adding the base and benzoyl chloride to the
- the compound shown in Formula 58 can be obtained by carrying out the benzoylation reaction in a mixture of the compound shown in Formula 57 and the solvent.
- Post-treatment may also be included in the step; the post-treatment may include the following steps: after the benzoylation reaction is finished, add 10% citric acid aqueous solution to quench the reaction, wash the separated organic phase, and concentrate That's it.
- the preparation method further includes the preparation method of the compound shown in formula 57, which includes the following steps:
- the operation and conditions of the benzyl esterification reaction can be conventional operations and conditions in this type of reaction in the art; for example, the solvent can be an ester solvent, such as ethyl acetate.
- the base can be an alkali metal carbonate, such as potassium carbonate.
- the phase transfer catalyst can be tetrabutylammonium bromide TBAB.
- the present invention provides a kind of preparation method of the diazabicyclooctane compound shown in formula 7, it comprises the following steps:
- the operations and conditions in the preparation method can be the same as the operations and conditions in the preparation of the compound shown in Formula 7 in the above-mentioned preparation method of the diazabicyclooctane compound shown in Formula 8.
- the present invention provides a kind of preparation method of the compound shown in formula 6, it comprises the steps:
- the operation and reaction conditions in the described preparation method can be the same as the operation and conditions in the preparation of the compound shown in formula 6 in the preparation method of the diazabicyclooctane compound shown in formula 8 as described above .
- the present invention provides a kind of preparation method of the compound shown in formula 5, it comprises the steps:
- the operation and reaction conditions in the described preparation method can be the same as the operation and conditions in the preparation of the compound shown in formula 5 in the preparation method of the diazabicyclooctane compound shown in formula 8 as described above .
- the present invention provides a kind of preparation method of the compound shown in formula 3, it comprises the steps:
- the compound shown in formula 59 is subjected to the following cyclopropylation reaction with a methylating reagent to obtain the compound shown in formula 3. ;
- the operations and reaction conditions in the described preparation method can be the same as the operations and conditions in the preparation of the compound shown in formula 3 in the preparation method of the diazabicyclooctane compound shown in formula 8 as described above .
- the present invention provides a method for preparing a compound as shown in formula 59, which comprises the following steps:
- the operations and reaction conditions in the preparation method can be the same as the operations and conditions in the preparation of the compound shown in formula 59 in the above-mentioned preparation method of the diazabicyclooctane compound shown in formula 8 .
- the present invention also provides a preparation method of the compound shown in formula 58, which comprises the following steps:
- the present invention provides a compound shown in formulas 5, 6, and 58,
- the present invention also provides a preparation method of oxadiazazole compounds and/or tautomers thereof, which comprises the following steps (a) and/or steps (b);
- the oxadiazazole compound shown can be;
- the solvent can be one or more of aromatic solvents, ether solvents, ester solvents and halogenated hydrocarbon solvents, and the aromatic solvent can be toluene,
- the ether solvent may be tetrahydrofuran
- the ester solvent may be ethyl acetate
- the halogenated hydrocarbon solvent may be dichloromethane.
- the solvent can be used in an amount that does not affect the reaction, for example, the volume-to-mass ratio of the solvent to the compound represented by Formula 18 can be 6.5 mL/g-10 mL/g.
- the dehydrating agent can be Burgess reagent (Burgess reagent, methyl N-(triethylsulfamoyl)carbamate).
- the molar ratio of the dehydrating agent to the compound represented by formula 18 may be 2:1 ⁇ 10:1; for example, 4.6:1.
- the base may be an organic base, such as N,N-diisopropylethylamine and/or triethylamine.
- the molar ratio of the base to the compound represented by formula 18 may be 4:1-6.5:1; for example, 4.1:1, 6.2:1.
- the ring-closing reaction is preferably carried out under inert gas, such as nitrogen and argon.
- the temperature of the ring-closing reaction may be from 10°C to 45°C, for example, from 25°C to 35°C.
- the progress of the ring-closing reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and the end point of the reaction is generally when the compound shown in formula 18 disappears or no longer reacts.
- the time for the ring-closing reaction is preferably 10 hours to 30 hours, for example, 20 hours.
- the step (a) may also include post-treatment; the post-treatment may include the following steps: after the ring-closing reaction is completed, add water to quench the reaction, and wash the separated organic phase.
- the quenching can be controlled by adding water with a mass ratio of 5-10 times the mass ratio of the compound shown in formula 18 at 15-25°C; the washing can be by adding the compound shown in formula 18 5-10 times the mass ratio of the compound for washing with saturated sodium chloride aqueous solution.
- the post-treated organic phase containing the compound shown in formula 20 can be directly fed into the next step reaction without purification.
- the organic solvent can be one or more of aromatic solvents, ether solvents, ester solvents and halogenated hydrocarbon solvents, and the aromatic solvent can be toluene , the ether solvent may be tetrahydrofuran, the ester solvent may be ethyl acetate, and the halogenated hydrocarbon solvent may be dichloromethane.
- the volume ratio of the water to the organic solvent may be 1.3:1 to 1:1.
- the solvent can be used in an amount that does not affect the reaction, for example, the mass ratio of the water to the compound shown in formula 19 can be 5-10 times.
- the acidic condition can be pH to 6-8; the acidic condition can be adjusted by adding 5% citric acid, and the adding temperature of 5% citric acid can be 15-25 °C.
- the temperature of the tautomerization reaction may be from 10°C to 45°C, for example, from 35°C to 45°C.
- the process of the tautomerization reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), generally when the compound shown in formula 19 disappears or no longer reacts as end point of the reaction.
- the time for the tautomerization reaction is preferably 10 hours to 30 hours, such as 20 hours.
- the post-treatment may also be included in the step (b); the post-treatment may include the following steps: after the tautomerization reaction is completed, add n-heptane, stir, and cool down to 5-15°C, Stir; filter, rinse with water, and dry.
- the n-heptane is preferably added dropwise, and the addition temperature of the n-heptane can be 15-25°C; the mass ratio of the n-heptane to the compound shown in formula 20 can be 3:1; the stirring time can be 3 hours; the mass ratio of the water in the rinsing to the compound shown in formula 20 can be 3:1.
- the hydrazide compound shown in formula 19 can be prepared by the step (a).
- step (a) it may also include the method for preparing the hydrazide compound shown in formula 18 and/or its tautomer, which includes the following step (c):
- the acid anhydride compound shown in formula 24 is amidated with the hydrazine compound shown in formula 17 and/or its tautomer to obtain the hydrazide shown in formula 18 Compounds and/or tautomers thereof;
- the solvent can be one or more of aromatic hydrocarbon solvents, ether solvents, ester solvents and halogenated hydrocarbon solvents
- the aromatic hydrocarbon solvents can be toluene
- the ether solvents can be is tetrahydrofuran
- the ester solvent can be ethyl acetate
- the halogenated hydrocarbon solvent can be dichloromethane.
- the solvent can be used in an amount that does not affect the reaction, for example, the volume-to-mass ratio of the solvent to the compound shown in Formula 17 can be 10 mL/g-20 mL/g.
- the molar ratio of the acid anhydride compound shown in formula 24 to the hydrazine compound shown in formula 17 and/or its tautomer can be 1.3:1 to 1:1.3; for example 1:1.2 .
- the temperature of the amidation reaction may be -15°C to 0°C, for example -10°C to 0°C.
- the amidation reaction is preferably carried out under an inert gas such as nitrogen and argon.
- the progress of the amidation reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and generally the end point of the reaction is when the compound shown in formula 24 disappears or no longer reacts.
- the amidation reaction time is preferably 1 hour to 3 hours, for example 1 hour.
- the step (c) may also include post-treatment; the post-treatment may include the following steps: after the amidation reaction is finished, after washing the organic phase, replace the organic solvent with ethyl acetate, and wash with water Finally, add methyl tert-butyl ether to mix and precipitate, filter, wash, and dry; the washing can be carried out with water and 5% sodium bicarbonate solution in sequence, and the amount of water and 5% sodium bicarbonate solution It can be 0.3 times the volume of the reaction system; preferably washed at 10 ° C; the replacement of the organic solvent can be the following steps: the washed organic phase, concentrated (to 2-4 times the volume of the product), add ( 4-5 times the volume of the product) ethyl acetate mixed, concentrated (to about 4 times the volume of the product), added (9-10 times the volume of the product) ethyl acetate and (2-3 times the volume of the product) water Mixing, separation and concentration of the organic phase (to 4-6 times the volume of the product) can be used
- the precipitation can be mixed by adding (3-5 times the volume of the product) methyl tert-butyl ether, cooling to precipitate solids; the mixing temperature can be 35-45 °C, and the cooling can be down to 10- 20°C; the washed solid can be filtered and washed with a mixed solution of ethyl acetate and methyl tert-butyl ether (volume ratio 1.2:1) (0.8-1 times the volume of the product).
- the raw materials for the amidation reaction are the acid anhydride compound shown in formula 24, the hydrazine compound shown in formula 17 and/or its tautomer and the solvent.
- Scheme (i) is a method for preparing the acid anhydride compound shown in formula 24, which includes the following step (d): in a solvent, in the presence of a base, the carboxylic acid compound shown in formula 9 and pivaloyl chloride is acylated to obtain the described acid anhydride compounds shown in formula 24,
- Scheme (ii) is a method for preparing the hydrazine compound shown in formula 17, which includes the following step (e): hydrazine and the nitrogen heterocyclic compound shown in formula 16 and/or its tautomerization
- the conformer is subjected to the hydrazide reaction as shown below to obtain the hydrazide compound shown in formula 17 and/or its tautomer,
- step (d) the molar ratio of the carboxylic acid compound shown in formula 9 to pivaloyl chloride may be 1:1 to 1:1.6; for example, 1:1.1.
- the solvent can be one or more of aromatic solvents, ether solvents, ester solvents and halogenated hydrocarbon solvents, the aromatic solvent can be toluene, and the ether solvent can be tetrahydrofuran , the ester solvent may be ethyl acetate, and the halogenated hydrocarbon solvent may be dichloromethane.
- the amount of the solvent can be used without affecting the reaction, for example, the volume to mass ratio of the solvent to the compound shown in formula 9 can be 10mL/g-20mL/g.
- the base can be an organic base, such as one or more of N,N-diisopropylethylamine DIPEA, pyridine and triethylamine.
- the molar ratio of the base to the carboxylic acid compound shown in Formula 9 may be 3:1 to 1:1; for example, 2:1.
- the acylation reaction is preferably carried out under inert gas, such as nitrogen and argon.
- the temperature of the acylation reaction may be -10-10°C, for example -10-0°C.
- the step (d) is preferably: after adding the base and pivaloyl chloride sequentially to the mixture of the compound shown in formula 9 and the solvent at below -5°C, Carry out the acylation reaction at -10-0°C to obtain the acid anhydride compound shown in formula 24.
- the progress of the acylation reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and generally the end point of the reaction is when the compound shown in formula 9 disappears or no longer reacts.
- the amidation reaction time is preferably 1 hour to 3 hours, such as 2.5 hours.
- step (e) the molar ratio of the hydrazine to the nitrogen heterocyclic compound represented by formula 16 and/or its tautomer may be 1.5:1 to 3:1.
- the hydrazine may be hydrazine hydrate, such as 80% hydrazine hydrate.
- Described solvent is one or more in alcoholic solvent, aromatic hydrocarbon solvent and halogenated alkanes; Described alcoholic solvent can be one or more in methyl alcohol, ethanol and Virahol, and described aromatic hydrocarbon
- the quasi-solvent can be toluene, and the halogenated alkane can be dichloromethane.
- the solvent can be used in an amount that does not affect the reaction, for example, the volume-to-mass ratio of the solvent to the compound represented by formula 16 can be 10 mL/g-20 mL/g, for example 12 mL/g.
- the hydrazidation reaction is preferably carried out under an inert gas such as nitrogen and argon.
- the temperature of the hydrazide reaction may be -20-10°C, for example -10-5°C.
- the step (e) is preferably: control the temperature below 5°C, add hydrazine to the mixture of the azacyclic compound shown in formula 16 and the solvent, and carry out the acyl Hydrazine reaction to obtain the hydrazide compound shown in formula 17 and/or its tautomer.
- the process of the hydrazidation reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and generally the compound shown in formula 16 disappears or no longer reacts as the reaction end point .
- the time for the hydrazidation reaction is preferably 1 hour to 3 hours, for example 1 hour.
- the step (e) may also include post-treatment; the post-treatment may include the following steps: after the hydrazide reaction is completed, sequentially add (10%) ammonium chloride aqueous solution and methylene chloride to mix, separate , the aqueous phase was extracted with dichloromethane, the organic phases were combined, washed with water, and concentrated; it could be directly used in the next amidation reaction.
- the molar ratio of the triphenylphosphine to the guanidine compound shown in formula 15 may be 1.1:1 to 1.3:1.
- the molar ratio of the imidazole to the guanidine compound represented by formula 15 may be 2.2:1 to 2.6:1.
- the molar ratio of the iodine to the guanidine compound represented by formula 15 may be 1.1:1 to 1.3:1.
- Described solvent can be nitrile solvent and/or halogenated hydrocarbon solvent, and described nitrile solvent can be acetonitrile, and described halogenated hydrocarbon solvent can be dichloromethane;
- the consumption of described solvent is not It only needs to affect the reaction, for example, the volume-to-mass ratio of the solvent to the compound shown in formula 15 can be 16mL/g-40mL/g.
- the temperature of the Appel reaction and the ring closure reaction may be -10°C to 10°C, for example -5°C to 5°C.
- the Appel reaction and ring-closing reaction are preferably carried out under inert gas, such as nitrogen and argon.
- Step (f) is preferably: the mixture of the guanidine compound shown in formula 15 and the solvent is added dropwise to the mixture of iodine, triphenylphosphine, imidazole and the solvent .
- Step (f) is preferably: at -5°C to 5°C, iodine is added in batches to the mixture of triphenylphosphine, imidazole and the solvent to obtain the reaction system 1, and then the formula
- the mixture of the guanidine compound shown in 15 and the solvent is added to the above reaction system 1 to perform the Appel reaction and the ring closure reaction to obtain the nitrogen heterocyclic compound shown in formula 16 and/or its Tautomers, yes.
- the mixture of the guanidine compound shown in Formula 15 and the solvent is preferably added dropwise into the reaction system 1.
- the progress of the ring-closing reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and generally the end point of the reaction is when the compound shown in formula 15 disappears or no longer reacts.
- the time for the Appel reaction and ring-closing reaction is preferably 1 hour to 3 hours, for example 1 hour.
- the step (f) may also include post-treatment; the post-treatment may include the following steps: after the ring-closing reaction is completed, add (5%) Na 2 SO 3 aqueous solution, and wash the separated organic phase with water , concentrate, add DMF and n-heptane (mass ratio ⁇ 14:1) to mix, concentrate, add water to mix, filter, filter cake is washed with DMF/water (volume ratio ⁇ 1:1), add ethyl acetate to dissolve, add water to wash ( 2 times), concentrate, add n-heptane and methyl tert-butyl ether (mass ratio ⁇ 1:1), mix, filter, filter cake washing, drying, to obtain the nitrogen heterocycle compound shown in formula 16 and/or its tautomers. For example, add (5%) Na 2 SO 3 aqueous solution at -5 ⁇ 5°C.
- the guanidine compound shown in formula 15 can be prepared by the following steps: in an organic solvent and water, in the presence of a base, combine the compound shown in formula 13 with the following steps: The compound shown in formula 14 is subjected to the imidization reaction shown below to obtain the guanidine compound shown in formula 15,
- the molar ratio of the compound shown in formula 13 to the compound shown in formula 14 may be 1:1.
- the organic solvent can be a nitrile solvent and/or a halogenated hydrocarbon solvent, the nitrile solvent can be acetonitrile, and the halogenated hydrocarbon solvent can be methylene chloride.
- the amount of the solvent should not affect the reaction, for example, the volume-to-mass ratio of the organic solvent to the compound shown in formula 14 can be 6mL/g-15mL/g, such as 8mL/g-10mL /g.
- the imidization reaction is preferably carried out under inert gas, such as nitrogen and argon.
- the temperature of the imidization reaction may be 10°C to 40°C, for example, 20°C to 30°C.
- the base may be alkali metal carbonate and/or bicarbonate, such as potassium carbonate and/or potassium bicarbonate.
- the mass ratio of the water to the alkali may be 1.5 to 2.5:1, for example 2:1.
- the process of the imidization reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), and generally the end point of the reaction is when the compound shown in formula 15 disappears or no longer reacts .
- the time for the imidization reaction is preferably 10 hours to 20 hours, for example, 16 hours.
- the step (f) may also include post-treatment; the post-treatment may include the following steps: after the imidization reaction is completed, add water to wash the organic phase (for example, twice), and concentrate the separated organic phase to obtain Can.
- the tautomer refers to the and and The compounds of the fragments are tautomers of each other.
- the present invention provides a nitrogen heterocyclic compound as shown in formula 16 and/or its tautomer, a hydrazine compound as shown in formula 17 and/or its tautomer, as shown in formula 24
- the present invention provides a method for preparing hydrazide compounds and/or tautomers thereof as shown in formula 18, which comprises the following steps:
- the acid anhydride compound shown in formula 24 is amidated with the hydrazine compound shown in formula 17 and/or its tautomer to obtain the hydrazide compound shown in formula 18 and / or its tautomers;
- the operation and reaction conditions in the preparation method of the hydrazide compound shown in formula 18 and/or its tautomer can be the same as the above-mentioned oxadiazole compound and/or its tautomer
- the operation and reaction conditions in the method for preparing the hydrazide compound shown in formula 18 and/or its tautomer in the method for preparing the isomer can be the same as the above-mentioned oxadiazole compound and/or its tautomer.
- the present invention provides a method for preparing an acid anhydride compound as shown in formula 24, which comprises the following steps: in a solvent, in the presence of a base, acylating a carboxylic acid compound as shown in formula 9 with pivaloyl chloride chemical reaction to obtain the described acid anhydride compounds shown in formula 24,
- the operations and reaction conditions in the preparation method of the acid anhydride compound shown in formula 24 and/or its tautomer can be the same as the above-mentioned oxadiazole compound and/or its tautomer Operation and reaction conditions in the method for preparing the acid anhydride compound shown in formula 24 and/or its tautomer in the method for preparing the body.
- the present invention provides a method for preparing hydrazine compounds and/or tautomers thereof as shown in formula 17, which comprises the following steps:
- the operation and reaction conditions in the preparation method of the hydrazine compound shown in formula 17 and/or its tautomer can be the same as the above-mentioned oxadiazole compound and/or its tautomer Operation and reaction conditions in the method for preparing the hydrazide compound shown in formula 17 and/or its tautomer in the preparation method of the body.
- the present invention provides a method for preparing nitrogen heterocyclic compounds and/or tautomers thereof as shown in formula 16, which comprises the following steps:
- reaction conditions and operations in the preparation method of the nitrogen-heterocyclic compounds shown in Formula 16 and/or their tautomers can be the same as those of the above-mentioned oxadiazole compounds and/or The reaction conditions and operations in the method for preparing the nitrogen heterocyclic compound represented by formula 16 and/or its tautomer in the preparation method of its tautomer.
- the invention provides a kind of preparation method of ⁇ -lactamase inhibitor and intermediate, and it is following scheme:
- Step (1) comprising the following steps (a) and/or steps (b),
- Step (2) In a solvent, in the presence of a palladium catalyst and hydrogen, the imidazoline compounds shown in formula 20 and/or their tautomers are subjected to the debenzylation reaction shown to obtain The hydroxylamine compound shown in formula 21 and/or its tautomer can be; the preparation of the imidazoline compound shown in formula 20 and/or its tautomer is the same as described above step (a) or (b);
- Step (1) Step (1) in the same scheme one;
- Step (2) Step (2) in the same scheme one;
- Step (3) In a solvent, in the presence of pyridine and a sulfonating reagent, carry out the sulfonation reaction of the hydroxylamine compound shown in formula 21 and/or its tautomer as shown, to obtain The sulfonic acid oxygen compound shown in formula 22 and/or its tautomer is enough;
- Scheme three the preparation method of imine compound as shown in formula I, it comprises the following steps:
- Steps (1) to (3) same as steps (1) to (3) in scheme two;
- Step (4) In water and an organic solvent, the sulfonic acid oxygen compound shown in formula 22 and/or its tautomer is subjected to the deamination protecting group reaction shown in the formula to obtain the formula The imine compounds shown in I get final product;
- step (1) of Scheme 1 the reaction operation and conditions are the same as those in the above-mentioned preparation method of oxadiazole compounds and/or their tautomers.
- described solvent can be one or more in alcohol solvent, ether solvent, amide solvent and halogenated hydrocarbon solvent; Described alcohol solvent can be methyl alcohol, One or more of ethanol and Virahol; the halogenated hydrocarbon solvent can be dichloromethane, the ether solvent can be tetrahydrofuran, and the amide solvent can be dimethylacetamide DMAc and/or N-methylpyrrolidone NMP. For example tetrahydrofuran.
- the amount of the solvent can be used without affecting the reaction, for example, the volume to mass ratio of the solvent to the imidazoline compound shown in formula 20 and/or its tautomer can be 15mL/g to 27mL/g.
- the palladium catalyst can be palladium carbon, palladium hydroxide; for example, 10% palladium carbon (dry basis).
- the mass ratio of the palladium catalyst to the imidazoline compound represented by formula 20 and/or its tautomer may be 0.02:1 to 0.9:1; for example, 0.09:1.
- the pressure of the hydrogen can be 0.3Mpa to 0.5Mpa.
- the temperature of the debenzylation reaction may be from 0°C to 40°C, for example, from 10°C to 20°C.
- the process of the debenzylation reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), generally with the imidazoline compound shown in formula 20 and/or its interconversion
- the end point of the reaction was when the isomer disappeared or no longer reacted.
- the time for the debenzylation reaction is preferably 10 hours to 30 hours, such as 24 hours.
- the scheme one may also include post-treatment; the post-treatment may include the following steps: after the debenzylation reaction is completed, add dimethyl sulfoxide to mix, filter, wash the filter cake with tetrahydrofuran, and combine the filtrates , add mercapto silica gel and activated carbon (mass ratio 1:1), mix, filter, wash the filter cake with tetrahydrofuran, combine the filtrates, concentrate, add water and acetonitrile (mass ratio 1.27:1), mix, filter, rinse, and dry.
- the post-treatment may include the following steps: after the debenzylation reaction is completed, add dimethyl sulfoxide to mix, filter, wash the filter cake with tetrahydrofuran, and combine the filtrates , add mercapto silica gel and activated carbon (mass ratio 1:1), mix, filter, wash the filter cake with tetrahydrofuran, combine the filtrates, concentrate, add water and acetonitrile (mass ratio 1.27:1), mix
- the consumption of described dimethyl sulfoxide can be 10 to 12 times of described imidazoline compound shown in formula 20 and/or its tautomer;
- the consumption of described mercapto silica gel and gac can be It is 0.16 times of the imidazoline compound shown in formula 20 and/or its tautomer;
- the amount of water and acetonitrile can be the imidazoline compound shown in formula 20 And/or 14 to 15 times its tautomers.
- described solvent can be halogenated hydrocarbon solvent and/or nitrile solvent; Described halogenated hydrocarbon solvent can be dichloromethane, and described nitrile solvent It can be acetonitrile. For example acetonitrile.
- the amount of the solvent can be used without affecting the reaction, for example, the volume to mass ratio of the solvent to the hydroxylamine compound shown in formula 21 and/or its tautomer can be from 5mL/g to 20mL/g.
- the sulfonating reagent can be one or more of pyridine sulfur trioxide, triethylamine sulfur trioxide and trimethylamine sulfur trioxide.
- the mass ratio of the pyridine sulfur trioxide to the hydroxylamine compound shown in formula 21 and/or its tautomer can be 1.2:1 to 6:1; for example, 1.2:1 to 5.97:1 .
- the mass ratio of the pyridine to the hydroxylamine compound represented by formula 21 and/or its tautomer may be 2.5:1 to 6.25:1.
- the temperature of the sulfonation reaction may be 15°C to 35°C, for example, 25°C to 35°C.
- the process of the sulfonation reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), generally with the hydroxylamine compound shown in formula 21 and/or its tautomer
- the end point of the reaction was when the body disappeared or no longer reacted.
- the time for the sulfonation reaction is preferably 5 hours to 10 hours, for example 6 hours.
- Post-treatment may also be included in the step (3) of the scheme two; the post-treatment may include the following steps: after the sulfonation reaction is finished, add activated carbon to mix, filter, wash the filter cake with acetonitrile, and combine the filtrate , you can. The filtrate can be directly used in the next reaction.
- the organic solvent can be a nitrile solvent; the nitrile solvent can be acetonitrile.
- the consumption of described water and organic solvent gets final product without affecting reaction, for example the volume mass ratio of described organic solvent and described sulfonic acid oxygen compound shown in formula 22 and/or its tautomer It can be from 9 mL/g to 11 mL/g.
- the temperature of the deamination-protecting group reaction may be 18°C to 40°C, for example, 30°C to 40°C.
- the process of the deamination protecting group reaction can be detected by conventional monitoring methods in the art (such as TLC, HPLC or NMR), generally with the sulfonic acid oxygen compound shown in formula 22 and/or its The end point of the reaction was when the tautomer disappeared or no longer reacted.
- the time for the deamination-protecting group reaction is preferably 3 hours to 10 hours, for example, 5 hours.
- the following purification steps may also be included: after the reaction is completed, cool down to 0°C to 10°C, precipitate solids, filter, wash the filter cake with 10% acetonitrile aqueous solution, and add dimethyl sulfoxide , heat up to 45-65°C and mix, add acetonitrile dropwise at this temperature, cool down to 0-10°C and mix, precipitate solid, filter, rinse the filter cake with acetonitrile, add water, control the temperature at 20-30°C, mix, cool down to 0-10°C, mix, precipitate solid, filter, wash the filter cake with water, and dry.
- the invention provides a kind of preparation method of ⁇ -lactamase inhibitor, it is characterized in that, it comprises the steps:
- Step 1 In a solvent, in the presence of a base and a phase transfer catalyst, the compound shown in formula 56 and benzyl bromide are subjected to the following benzyl esterification reaction to obtain the compound shown in formula 57;
- Step 2 In a solvent, in the presence of a base, perform the benzoylation reaction of the compound shown in formula 57 with benzoyl chloride as shown below to obtain the compound shown in formula 58;
- Step 3 In a solvent, in the presence of an alkali, aqueous formaldehyde solution or paraformaldehyde, and a phase transfer catalyst, the compound shown in formula 58 is subjected to the following reaction to obtain the compound shown in formula 59;
- Step 4 In a solvent, in the presence of Zn/Cu or Zn/Ag reagent, the compound shown in formula 59 is subjected to the following cyclopropylation reaction with a methylating reagent to obtain the compound shown in formula 3 compound;
- Step 5 In a solvent, in the presence of a base, the compound shown in formula 3 is subjected to the following ring-opening reaction with trimethylsulfoxide iodide to obtain the compound 4;
- Step 6 In a solvent, in the presence of a catalyst and a ligand, the compound shown in Formula 4 is subjected to the following ring-closing reaction to obtain the compound 5;
- Step 7 In a solvent, in the presence of a base, perform a Schiff base reaction on the compound shown in formula 5 and O-phenylhydroxylamine or its salt to obtain the compound 6;
- Step 8 (1) In a solvent, in the presence of sulfuric acid, the compound shown in formula 6 is reacted with an acid to obtain a mixture A; (2) a reducing agent is added to the mixture A for a reduction reaction to obtain a compound as shown in formula 7 the indicated compound;
- Step 9 Add the mixture of triphosgene and solvent to the compound shown in formula 7 and/or its salt, alkali and solvent mixture, and carry out the amidation ring closure reaction as shown below to obtain the compound shown in formula 8 Diazabicyclooctane compounds;
- Step 10 In an organic solvent and water, add a base to the compound shown in formula 8, and hydrolyze to obtain the compound shown in formula 9;
- Step 11 In a solvent, in the presence of a base, acylate the carboxylic acid compound shown in Formula 9 with pivaloyl chloride to obtain the acid anhydride compound shown in Formula 24;
- Step 12 In an organic solvent and water, in the presence of a base, carry out the following imidization reaction between the compound shown in formula 13 and the compound shown in formula 14 to obtain the compound shown in formula 15 guanidine compounds;
- Step 13 In a solvent, in the presence of triphenylphosphine, imidazole and iodine, the guanidine compound shown in formula 15 is subjected to the Appel reaction and ring closure reaction shown below to obtain the compound shown in formula 16
- Step 14 Carrying out the hydrazide reaction of hydrazine with the azacyclic compound shown in formula 16 and/or its tautomer as shown below to obtain the hydrazides shown in formula 17 compounds and/or tautomers thereof;
- Step 15 Carrying out amidation reaction between the acid anhydride compound shown in formula 24 and the hydrazine compound shown in formula 17 and/or its tautomer to obtain the hydrazide shown in formula 18 Compounds and/or their tautomers;
- Step 16 In a solvent, in the presence of a dehydrating agent and a base, subject the hydrazide compound shown in formula 18 and/or its tautomer to the ring-closing reaction shown in the formula 19 to obtain Oxadiazole compounds and/or their tautomers;
- Step seventeen in an organic solvent and water, under acidic conditions, carry out the tautomerization reaction of the hydrazide compound shown in formula 19 to obtain its tautomer, as shown in formula 20 Oxadiazole compounds;
- Step 18 In a solvent, in the presence of a palladium catalyst and hydrogen, carry out the debenzylation reaction of the imidazoline compound shown in formula 20 and/or its tautomer to obtain the following: The hydroxylamine compound represented by formula 21 and/or its tautomer;
- Step 19 In a solvent, in the presence of pyridine and a sulfonating reagent, carry out the sulfonation reaction of the hydroxylamine compound shown in formula 21 and/or its tautomer to obtain the formula Sulfonic acid oxygen compounds shown in 22 and/or their tautomers;
- Step 20 In water and an organic solvent, subject the sulfonic acid oxygen compound shown in formula 22 and/or its tautomer to the deaminated protecting group reaction shown in the formula I The imine compounds shown.
- each step of the reaction in the preparation method can be the same as the operation and conditions of the corresponding reaction in any of the above-mentioned schemes in the present invention.
- the reagents and raw materials used in the present invention are all commercially available.
- the positive progress effect of the present invention lies in: adopting the method provided by the present invention to prepare the ⁇ -lactamase inhibitor and intermediate, the cost is low, and the repeatability and scalability of key reactions are improved, which is significantly better than that of the prior art.
- the method improves the total yield, reduces the number of reaction steps, and has the technical advantages of being green, safe, efficient and simple; it is suitable for industrial production.
- Zn/Ag reagent preparation nitrogen protection in the reaction kettle, add 50ml of acetic acid, stir, add 50mg of silver acetate, heat the system to reflux, add 5.58g of zinc powder, cool the system to 20-30°C, filter, add the filter cake to the reaction kettle, Add 50ml of tetrahydrofuran, stir for 30 minutes, filter, add the filter cake to the reaction kettle, add 50ml of tetrahydrofuran, stir for 30 minutes, filter, and dry the filter cake to obtain 5.2g of Zn/Ag reagent.
- reaction solution was cooled to 10-30°C, 30g of water was added to the reaction solution, stirred, allowed to stand and separated, and the organic phase was collected to obtain 36g of XNW210002 ethyl acetate solution with a purity of 97.5%, a content of 35.6%, and a yield of 93.4%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (17)
- 一种β-内酰胺酶抑制剂的制备方法,其特征在于,其包括如下步骤;步骤一:在溶剂中,在碱和相转移催化剂存在下,将如式56所示的化合物和溴苄进行所示的苄酯化反应,得到所述的如式57所示的化合物;步骤二:在溶剂中,在碱存在下,将如式57所示的化合物与苯甲酰氯进行所示的苯甲酰化反应,得到所述的如式58所示的化合物;步骤三:在溶剂中,在碱、甲醛水溶液或多聚甲醛、相转移催化剂存在下,将如式58所示的化合物进行所示的反应,得到如式59所示的化合物,即可;步骤四:在溶剂中,在Zn/Cu或Zn/Ag试剂存在下,将如式59所示的化合物与甲基化试剂进行所示的环丙基化反应,得到如式3所示的化合物;步骤五:在溶剂中,在碱存在下,将如式3所示的化合物与三甲基碘化亚砜进行所示的开环反应,得到所述的化合物4;步骤六:在溶剂中,在催化剂和配体存在下,将如式4所示的化合物进行所示的关环反应,得到所述的化合物5;步骤七:在溶剂中,在碱存在下,将如式5所示的化合物与O-苯基羟胺或其盐进行席夫碱反应,得到所述的化合物6;步骤八:(1)在溶剂中,在硫酸存在下,将如式6所示的化合物与酸进行反应,得到混合物A;(2)将还原剂加入混合物A中进行还原反应,得到如式7所示的化合物;步骤九:将三光气和溶剂的混合物加入到如式7所示的化合物和/或其盐、碱和溶剂的混合物中,进行所示的酰胺化关环反应,得到如式8所示的二氮杂二环辛烷类化合物;步骤十:在有机溶剂和水中,将碱加入到式8所示的化合物中,水解得到如式9所示的化合物;步骤十一:在溶剂中,在碱存在下,将如式9所示的羧酸类化合物与特戊酰氯进行酰化反应,得到所述的如式24所示的酸酐类化合物;步骤十二:在有机溶剂和水中,在碱存在下,将如式13所示的化合物与如式14所示的化合物进行所示的亚胺化反应,得到所述的如式15所示的胍类化合物;步骤十三:在溶剂中,在三苯基膦、咪唑和碘存在下,将如式15所示的胍类化合物进行所示的Appel反应和关环反应,得到所述的如式16所示的氮杂环类化合物和/或其互变异构体;步骤十四:将肼与如式16所示的氮杂环类化合物和/或其互变异构体进行所示的酰肼化反应,得到所述的如式17所示的酰肼类化合物和/或其互变异构体;步骤十五:将如式24所示的酸酐类化合物与如式17所示的肼类化合物和/或其互变异构体进行酰胺化反应,得到所述的如式18所示的酰肼类化合物和/或其互变异构体;步骤十六:在溶剂中,在脱水剂和碱存在下,将如式18所示的酰肼类化合物和/或其互变异构体进行所示的关环反应,得到如式19所示的氧杂二氮唑类化合物和/或其互变异构体;步骤十七:在有机溶剂和水中,在酸性条件下,将如式19所示的酰肼类化合物进行所示的互变异构化反应,得到其互变异构体,如式20所示的氧杂二氮唑类化合物;步骤十八:在溶剂中,在钯催化剂和氢气存在下,将所述的如式20所示的咪唑啉类化合物和/或其互变异构体进行所示的脱苄基反应,得到如式21所示的羟胺类化合物和/或其互变异构体;步骤十九:在溶剂中,在吡啶和磺化试剂存在下,将所述的如式21所示的羟胺类化合物和/或其互变异构体进行所示的磺酸化反应,得到如式22所示的磺酸氧类化合物和/或其互变异构体;步骤二十:在水和有机溶剂中,将所述的如式22所示的磺酸氧类化合物和/或其互变异构体进行所示的脱胺基保护基反应,得到如式I所示的亚胺类化合物。
- 如权利要求1所述的制备方法,其特征在于,在步骤一中,其满足如下条件中的一种或多种:(1)所述的溶剂为酯类溶剂,例如乙酸乙酯;(2)所述的碱为碱金属碳酸盐,例如碳酸钾;(3)所述的相转移催化剂为四丁基溴化铵;在步骤二中,其满足如下条件中的一种或多种:(1)所述的溶剂为酮类溶剂、腈类溶剂、醚类溶剂、酯类溶剂和卤代烃类溶剂中的一种或多种, 所述的酮类溶剂可为丙酮,所述的腈类溶剂可为乙腈,所述的醚类溶剂可为四氢呋喃,所述的酯类溶剂可为乙酸乙酯,所述的卤代烃类溶剂可为二氯甲烷;(2)所述的溶剂与所述的如式57所示的化合物的体积质量比为5mL/g-10mL/g;(3)所述的苯甲酰氯与所述的如式57所示的化合物的摩尔比为1.05:1至1.1:1;(4)所述的碱为碱金属的醇化物和/或双(三甲基硅基)胺基锂,所述的碱金属醇化物可为叔丁醇钠,叔丁醇锂和叔丁醇钾中的一种或多种;(5)所述的碱与所述的如式57所示的化合物的摩尔比为1.4:1至2.5:1;(6)所述的苯甲酰化反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(7)所述的苯甲酰化反应的温度为-65℃至25℃,例如-15℃至-5℃;(8)所述的制备所述的如式58所示的化合物的方法,其包括如下步骤:于-15℃至-5℃,将所述的碱、苯甲酰氯依次至所述的如式57所示的化合物和所述的溶剂的混合物中进行所述的苯甲酰化反应,得到所述的如式58所示的化合物;在所述步骤三中,其满足如下条件中的一种或多种:(1)所述的溶剂为醚类溶剂、卤代烃类溶剂、腈类溶剂、酮类溶剂、酯类溶剂和N,N-二甲基甲酰胺中的一种或多种,所述的醚类溶剂可为四氢呋喃和/或1,4-二氧六环,所述的卤代烃类溶剂可为二氯甲烷,所述的酯类溶剂可为乙酸乙酯,所述的腈类溶剂可为乙腈,所述的酮类溶剂可为丙酮;(2)所述的溶剂与所述的如式58所示的化合物的体积质量比为8mL/g-12mL/g;(3)所述的相转移催化剂为季铵盐,例如四正丁基碘化铵和/或四丁基氟化铵三水合物;(4)所述的相转移催化剂与所述的如式58所示的化合物的摩尔比为0.04:1~0.05:1;例如0.045:1;(5)所述的碱为无机碱和/或有机碱,所述的无机碱可为碱金属碳酸盐、碱金属的碳酸氢盐和碱金属醇化物中的一种或多种,所述的碱金属碳酸盐可为碳酸钾和/或碳酸铯,所述的碱金属碳酸氢盐可为碳酸氢钾和/或碳酸氢钠,所述的碱金属醇化物可为叔丁醇钾,所述的有机碱可为三乙胺和/或二异丙胺;(6)所述的碱与所述的如式58所示的化合物的摩尔比为2:1至3:1;(7)所述的甲醛水溶液里的甲醛或多聚甲醛与所述的如式58所示的化合物的摩尔比为1:1至6:1;例如3.4:1;(8)所述的步骤中,所述的碱与所述的甲醛水溶液或多聚甲醛分批加入,例如平均分3次加入;(9)所述的反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(10)所述的反应的温度为15℃至55℃,例如35℃至45℃;在所述步骤四中,其满足如下条件中的一种或多种:(1)所述的溶剂为酰胺类溶剂,例如DMF;(2)所述的溶剂与所述的如式59所示的化合物的体积质量比为5mL/g-30mL/g;例如10mL/g;(3)所述的Zn/Cu或Zn/Ag试剂与所述的如式59所示的化合物的摩尔比为0.5:1至3:1;例如2:1;(4)所述的甲基化试剂为二溴甲烷和/或二碘甲烷;(5)所述的甲基化试剂与所述的如式59所示的化合物的摩尔比为01.5:1至3:1;例如2:1;(6)所述的环丙基化反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(7)所述的环丙基化反应的温度为15℃至45℃,例如30℃至40℃;在所述步骤五中,其满足如下条件中的一种或多种:(1)所述的溶剂为醚类溶剂和二甲基亚砜的混合物,所述的醚类溶剂可为四氢呋喃;(2)所述的醚类溶剂与二甲基亚砜的体积比为1:1.2至3:1,例如5:3;(3)所述的碱为碱金属的醇化物,例如叔丁醇钾;(4)所述的碱与所述的如式3所示的化合物的摩尔比为1:1至1.4:1;例如1.15:1至1.2:1;(5)所述的三甲基碘化亚砜与所述的如式3所示的化合物的摩尔比为1:1至1.4:1;例如1.15:1至1.2:1;(6)所述的开环反应在惰性气体下进行,所述的惰性气体可为氩气或氮气;(7)所述的开环反应的温度为-20~30℃;(8)所述的步骤为:将碱与三甲基碘化亚砜在部分醚类溶剂与二甲基亚砜中进行混合后,依次加入剩余部分的醚类溶剂及所述的如式3所示的化合物,进行所述的开环反应;所述的混合的温度可为20~30℃;所述的开环反应的温度可为-10~0℃;在所述步骤六中,其满足如下条件中的一种或多种:(1)所述的溶剂为芳烃类溶剂、醇类溶剂、醚类溶剂、酰胺类溶剂和酯类溶剂中的一种或多种;所述的芳烃类溶剂可为甲苯,所述的醇类溶剂可为叔戊醇和/或特戊醇,所述的醚类溶剂可为环戊基甲醚和/或四氢呋喃,所述的酰胺类溶剂可为DMAc和/或DMF,所述的酯类溶剂可为醋酸异丙酯;(2)所述的溶剂与所述的如式4所示的化合物的体积质量比为2mL/g-3mL/g;(3)所述的催化剂为二(三苯基膦)环戊二烯基氯化钌(II),1,5-环辛二烯氯化铱二聚体,甲氧基(环辛二烯)合铱二聚体,醋酸铜,碘化亚铜,醋酸钯(II),反-二(乙氰)二氯化钯(II)和三氟乙酸钯中的一种或多种,例如二(三苯基膦)环戊二烯基氯化钌(II);(4)所述的催化剂与所述的如式4所示的化合物的摩尔比为0.01至0.1,例如0.015:1;(5)所述的关环反应中还加入配体,所述的配体可为三苯基膦;(6)所述的关环反应中还加入配体,所述的配体与所述的如式4所示的化合物的摩尔比为0.01至0.1,例如0.04:1;(7)所述的关环反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(8)所述的关环反应的温度为60℃至110℃,例如95℃至105℃;在所述步骤七中,其满足如下条件中的一种或多种:(1)所述的溶剂为醇类溶剂和/或酯类溶剂;所述的醇类溶剂可为乙醇,异丙醇,叔丁醇和叔戊醇中的一种或多种,所述的酯类溶剂可为乙酸乙酯;(2)所述的溶剂与所述的如式5所示的化合物的体积质量比为8mL/g-12mL/g;(3)所述的如式5所示的化合物与O-苯基羟胺或其盐的摩尔比为1.15:1至1.5:1,例如1.5:1;(4)所述的O-苯基羟胺盐为其盐酸盐;(5)所述的碱为碱金属碳酸氢盐,例如碳酸氢钠;(6)所述的碱与所述的O-苯基羟胺的盐的摩尔比为2:1.5;(7)所述的碱与所述的如式5所示的化合物的摩尔比为1.5:1至2:1,例如2:1;(8)所述的席夫碱反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(9)所述的席夫碱反应的温度为15℃至45℃,例如15℃至25℃;(10)所述的制备所述的化合物6的方法,其包括如下步骤:在溶剂中,于15℃至25℃,将所述的碱加入所述的O-苯基羟胺或其盐和溶剂的混合物中,再加入所述的如式5所示的化合物与溶剂的混合物,进行所述的席夫碱反应,得到所述的化合物6;在所述步骤八中,其满足如下条件中的一种或多种:(1)所述步骤(1)中,所述的溶剂为酯类溶剂,例如乙酸乙酯;(2)所述步骤(1)中,所述的溶剂与所述的如式6所示的化合物的体积质量比为9mL/g-15mL/g,例如12mL/g;(3)所述步骤(1)中,所述的硫酸与所述的化合物6的摩尔比为4:1至12:1;(4)所述步骤(1)中,所述的硫酸以浓硫酸与所述的溶剂的溶液形式加入;所述的溶液中,浓硫酸与所述的溶剂的质量比可为1.4:1;(5)步骤(1)的反应温度为-45℃至-5℃,例如-35℃至-25℃;(6)步骤(1)的反应结束后,不经后处理直接用于步骤(2)进行所述的还原反应制备所述的化合物7;(7)所述步骤(2)中,所述的还原剂为硼氢化钠,硼烷甲基硫醚,三乙基硼氢化锂;例如硼氢化钠;(8)所述步骤(2)中,所述的还原剂与所述的如式6所示的化合物的摩尔比为4:1至6:1;例如4:1;(9)所述步骤(2)中,所述的还原反应的温度为-70℃至-35℃,例如-70℃至-60℃;在所述步骤九中,其满足如下条件中的一种或多种:(1)所述的溶剂为乙腈、卤代烃类溶剂和芳烃类溶剂中的一种或多种,所述的卤代烃类溶剂例如二氯甲烷,所述的芳烃类溶剂例如甲苯;(2)三光气在所述的三光气和溶剂的混合物中的质量百分比为10%;(3)所述的如式7所示的化合物和/或其盐、碱和溶剂的混合物中,所述的溶剂与所述的如式7所示的化合物和/或其盐的体积质量比为3mL/g;(4)所述的如式7所示的化合物的盐为盐酸盐,例如2当量的盐酸;(5)所述的碱为有机碱,例如N,N-二异丙基乙胺和/或三乙胺;(6)所述的碱与所述的如式7所示的化合物的摩尔比为4:1;或者,所述的碱与所述的如式7所 示的化合物的盐的摩尔比为6:1;(7)所述的三光气与所述的如式7所示的化合物和/或其盐的摩尔比为0.35:1至0.5:1;例如0.38:1至0.4:1;(8)所述的所示的酰胺化关环反应的温度为-10℃至0℃;(9)所述的酰胺化关环反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(10)所述的制备方法为如下步骤:内温10℃至30℃下加入所述的碱至所述的如式7所示的化合物和/或其盐和溶剂的混合物中后,-10~0℃下加入10%三光气和溶剂的溶液,进行所示的酰胺化关环反应,得到如式8所示的二氮杂二环辛烷类化合物即可;在所述步骤十中,其满足如下条件中的一种或多种:(1)所述的如式8所示的二氮杂二环辛烷类化合物与碱的摩尔比为1:1至1:0.9;(2)所述的有机溶剂为丙酮;(3)所述有机溶剂和水的体积比为4:1至3:1;(4)所述的碱为氢氧化钾为水溶液,例如85%氢氧化钾水溶液;(5)所述的水解反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(6)所述水解反应的温度为-10~10℃,例如-10~0℃;在所述步骤十一中,其满足如下条件中的一种或多种:(1)所述的如式9所示的羧酸类化合物与特戊酰氯的摩尔比为1:1至1:1.6;例如1:1.1;(2)所述的溶剂为芳烃类溶剂、醚类溶剂、酯类溶剂和卤代烃类溶剂中的一种或多种;所述的芳烃类溶剂可为甲苯,所述的醚类溶剂可为四氢呋喃,所述的酯类溶剂可为乙酸乙酯,所述的卤代烃类溶剂可为二氯甲烷;(3)所述的溶剂与所述的如式9所示的化合物的体积质量比为10mL/g-20mL/g;(4)所述的碱为有机碱,例如N,N-二异丙基乙胺、吡啶和三乙胺中的一种或多种;(5)所述的碱与所述的如式9所示的羧酸类化合物的摩尔比为3:1至1:1;例如2:1;(6)所述的酰化反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(7)所述酰化反应的温度为-10~10℃,例如-10~0℃;(8)于-5℃以下,将所述的碱、特戊酰氯依次加入到所述的如式9所示的化合物与所述的溶剂的混合物中后,于-10~0℃进行所述的酰化反应,得到所述的如式24所示的酸酐类化合物;(9)所述的酰化反应结束后不经后处理直接用于所述的酰胺化反应;在所述的步骤十二中,其满足如下条件中的一种或多种:(1)所述的如式13所示的化合物与所述的如式14所示的化合物的摩尔比为1:1;(2)所述的有机溶剂为腈类溶剂和/或卤代烃类溶剂;所述的腈类溶剂可为乙腈,所述的卤代烃类溶剂可为二氯甲烷;(3)所述的有机溶剂与所述的如式14所示的化合物的体积质量比为6mL/g-15mL/g,例如8mL/g-10mL/g;(4)所述的亚胺化反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(5)所述亚胺化反应的温度为10℃至40℃,例如20℃至30℃;(6)所述的碱为碱金属的碳酸盐和/或碱金属的碳酸氢盐,例如碳酸钾和/或碳酸氢钾;(7)所述的水与所述的碱的质量比为1.5至2.5:1,例如2:1;在所述的步骤十三中,其满足如下条件中的一种或多种:(1)所述的三苯基膦与所述的如式15所示的胍类化合物的摩尔比为1.1:1至1.3:1;(2)所述的咪唑与所述的如式15所示的胍类化合物的摩尔比为2.2:1至2.6:1;(3)所述的碘与所述的如式15所示的胍类化合物的摩尔比为1.1:1至1.3:1;(4)所述的溶剂为腈类溶剂和/或卤代烃类溶剂;所述的腈类溶剂可为乙腈,所述的卤代烃类溶剂可为二氯甲烷;(5)所述的溶剂与所述的如式15所示的化合物的体积质量比为16mL/g-40mL/g;(6)所述Appel反应和关环反应的温度为-10℃至10℃,例如-5℃至5℃;(7)所述的Appel反应和关环反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(8)所述的如式15所示的胍类化合物和所述的溶剂的混合物滴加到所述的碘、三苯基膦、咪唑和所述的溶剂的混合物中;(9)于-5℃至5℃,将碘分批加入到三苯基膦、咪唑和所述的溶剂的混合物中得到反应体系1后,再将所述的如式15所示的胍类化合物和所述的溶剂的混合物加入上述反应体系1中进行所述的Appel反应和关环反应,得到所述的如式16所示的氮杂环类化合物和/或其互变异构体;在所述的步骤十四中,其满足如下条件中的一种或多种:(1),所述的肼与如式16所示的氮杂环类化合物和/或其互变异构体的摩尔比为1.5:1至3:1;(2)所述的肼为水合肼,例如80%的水合肼;(3)所述的溶剂为醇类溶剂、芳烃类溶剂和卤代烷烃中的一种或多种;所述的醇类溶剂可为甲醇、乙醇和异丙醇中的一种或多种,所述的芳烃类溶剂可为甲苯,所述的卤代烷烃可为二氯甲烷;(4)所述的溶剂与所述的如式16所示的化合物的体积质量比为10mL/g-20mL/g,例如12mL/g;(5)所述的酰肼化反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(6)所述酰肼化反应的温度为-20~10℃,例如-10~5℃;(7)控制温度在5℃以下,将肼加入到所述的如式16所示的氮杂环类化合物和所述溶剂的混合物中,进行所述的酰肼化反应,得到所述的如式17所示的酰肼类化合物和/或其互变异构体;在所述的步骤十五中,其满足如下条件中的一种或多种:(1)所述的溶剂为芳烃类溶剂、醚类溶剂、酯类溶剂和卤代烃类溶剂中的一种或多种,所述的芳烃类溶剂可为甲苯,所述的醚类溶剂可为四氢呋喃,所述的酯类溶剂可为乙酸乙酯,所述的卤代烃类溶剂可为二氯甲烷;(2)所述的溶剂与所述的如式17所示的化合物的体积质量比为10mL/g-20mL/g;(3)所述的如式24所示的酸酐类化合物与所述的如式17所示的肼类化合物和/或其互变异构体 得摩尔比为1.3:1至1:1.3;例如1:1.2;(4)所述酰胺化反应的温度为-15℃至0℃,例如-10℃至0℃;(5)其为如下步骤:控制温度在-10~0℃,将所述的如式24所示的酸酐类化合物和所述溶剂的混合物加入到所述的如式17所示的化合物和所述溶剂的混合物中,进行所述的酰胺化反应,得到所述的如式18所示的酰肼类化合物和/或其互变异构体;(6)所述的酰胺化反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(7)所述的酰胺化反应的原料为所述的如式24所示的酸酐类化合物与如式17所示的肼类化合物和/或其互变异构体以及所述的溶剂;在所述的步骤十六中,其满足如下条件中的一种或多种:(1)所述的溶剂为芳烃类溶剂、醚类溶剂、酯类溶剂和卤代烃类溶剂中的一种或多种;所述的芳烃类溶剂可为甲苯,所述的醚类溶剂可为四氢呋喃,所述的酯类溶剂可为乙酸乙酯,所述的卤代烃类溶剂可为二氯甲烷;(2)所述的溶剂与所述的如式18所示的化合物的体积质量比为6.5mL/g-10mL/g;(3)所述的脱水剂为伯吉斯试剂;(4)所述的脱水剂与所述的如式18所示的化合物的摩尔比为2:1~10:1;例如4.6:1(5)所述的碱为有机碱;例如N,N-二异丙基乙胺和/或三乙胺;(6)所述的碱与所述的如式18所示的化合物的摩尔比为4:1~6.5:1;例如4.1:1、6.2:1;(7)所述的关环反应在惰性气体下进行,所述的惰性气体例如氮气、氩气;(8)所述的关环反应的温度为10℃至45℃,例如25℃至35℃在所述的步骤十七中,其满足如下条件中的一种或多种:(1)所述的有机溶剂为芳烃类溶剂、醚类溶剂、酯类溶剂和卤代烃类溶剂中的一种或多种,所述的芳烃类溶剂可为甲苯,所述的醚类溶剂可为四氢呋喃,所述的酯类溶剂可为乙酸乙酯,所述的卤代烃类溶剂可为二氯甲烷;(2)所述的水与所述的有机溶剂的体积比为1.3:1至1:1;(3)所述的水与所述的如式19所示的化合物的质量比为5-10倍;(4)所述的酸性条件为pH至6~8;(5)所述的酸性条件为加入5%柠檬酸调节得到,所述5%柠檬酸加入温度可为15~25℃;在所述的步骤十八中,其满足如下条件中的一种或多种:(1)所述的溶剂为醇类溶剂、醚类溶剂、酰胺类溶剂和卤代烃类溶剂中的一种或多种;所述的醇类溶剂可为甲醇、乙醇和异丙醇中的一种或多种;所述的卤代烃类溶剂可为二氯甲烷,所述的醚类溶剂可为四氢呋喃,所述的酰胺类溶剂可为二甲基乙酰胺和/或N-甲基吡咯烷酮;(2)所述的溶剂与所述的如式20所示的咪唑啉类化合物和/或其互变异构体的体积质量比为15mL/g至27mL/g;(3)所述的钯催化剂为钯炭、氢氧化钯;例如10%钯炭;(4)所述的钯催化剂与所述的如式20所示的咪唑啉类化合物和/或其互变异构体的质量比为0.02:1至0.9:1;例如0.09:1;(5)所述的氢气的压力为0.3Mpa至0.5Mpa;(6)所述的脱苄基反应的温度为0℃至40℃,例如10℃至20℃;在所述的步骤十九中,其满足如下条件中的一种或多种:(1)所述的溶剂为卤代烃类溶剂和/或腈类溶剂;所述的卤代烃类溶剂可为二氯甲烷,所述的腈类溶剂可为乙腈;(2)所述的溶剂与所述的如式21所示的羟胺类化合物和/或其互变异构体的体积质量比为5mL/g至20mL/g;(3)所述的磺化试剂为三氧化硫吡啶、三氧化硫三乙胺和三氧化硫三甲胺中的一种或多种;(4)所述的三氧化硫吡啶与所述的如式21所示的羟胺类化合物和/或其互变异构体的质量比为1.2:1至6:1;(5)所述的吡啶与所述的如式21所示的羟胺类化合物和/或其互变异构体的质量比为2.5:1至6.25:1;(6)所述的磺酸化反应的温度为15℃至35℃,例如25℃至35℃;在所述的步骤二十中,其满足如下条件中的一种或多种:(1)所述的有机溶剂为腈类溶剂;所述的腈类溶剂可为乙腈;(2)所述的有机溶剂与所述的如式22所示的磺酸氧类化合物和/或其互变异构体的体积质量比为9mL/g至11mL/g;(3)所述的脱胺基保护基反应的温度为18℃至40℃,例如30℃至40℃。
- 一种β-内酰胺酶抑制剂及中间体的制备方法,其特征在于,其为如下任一方案:方案一、如式21所示的羟胺类化合物和/或其互变异构体的制备方法,其包括如下步骤:步骤(1):包括如下步骤(a)和/或步骤(b),步骤(a):在溶剂中,在脱水剂和碱存在下,将如式18所示的酰肼类化合物和/或其互变异构体进行所示的关环反应,得到如式19所示的氧杂二氮唑类化合物和/或其互变异构体;步骤(b):在溶剂中,在酸性条件下,将如式19所示的酰肼类化合物进行所示的互变异构化反应,得到其互变异构体,如式20所示的氧杂二氮唑类化合物;步骤(2):在溶剂中,在钯催化剂和氢气存在下,将所述的如式20所示的咪唑啉类化合物和/或其互变异构体进行所示的脱苄基反应,得到如式21所示的羟胺类化合物和/或其互变异构体;方案二、如式21所示的羟胺类化合物和/或其互变异构体的制备方法,其包括如下步骤:步骤(1):同方案一中的步骤(1);步骤(2):同方案一中的步骤(2);步骤(3):在溶剂中,在吡啶和磺化试剂存在下,将所述的如式21所示的羟胺类化合物和/或其互变异构体进行所示的磺酸化反应,得到如式22所示的磺酸氧类化合物和/或其互变异构体;方案三、如式I所示的亚胺类化合物的制备方法,其包括如下步骤:步骤(1)至(3):同方案二中的步骤(1)至(3);步骤(4):在水和有机溶剂中,将所述的如式22所示的磺酸氧类化合物和/或其互变异构体进行所示的脱胺基保护基反应,得到如式I所示的亚胺类化合物;
- 如权利要求16所述的制备方法其特征在于,所述制备方法满足如下条件中的一种或多种:(1)方案一中,所述的制备方法中的反应操作和条件同权利要求1-2中任一项所述的制备方法中相应的反应操作和条件;(2)方案二中,所述的制备方法中的反应操作和条件同权利要求1-2中任一项所述的制备方法中相应的反应操作和条件;(3)方案三中,所述的制备方法中的反应操作和条件同权利要求1-2中任一项所述的制备方法中相应的反应操作和条件。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022393742A AU2022393742A1 (en) | 2021-11-17 | 2022-11-17 | β-LACTAMASE INHIBITOR INTERMEDIATE AND PREPARATION METHOD THEREFOR |
CA3238268A CA3238268A1 (en) | 2021-11-17 | 2022-11-17 | ?-lactamase inhibitor intermediate and preparation method therefor |
CN202280076434.2A CN118215665A (zh) | 2021-11-17 | 2022-11-17 | β-内酰胺酶抑制剂中间体及制备方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111364826.2 | 2021-11-17 | ||
CN202111364826 | 2021-11-17 | ||
CN202111364821 | 2021-11-17 | ||
CN202111364821.X | 2021-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023088375A1 true WO2023088375A1 (zh) | 2023-05-25 |
Family
ID=86396282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/132591 WO2023088375A1 (zh) | 2021-11-17 | 2022-11-17 | β-内酰胺酶抑制剂中间体及制备方法 |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN118215665A (zh) |
AU (1) | AU2022393742A1 (zh) |
CA (1) | CA3238268A1 (zh) |
WO (1) | WO2023088375A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117720106A (zh) * | 2023-12-28 | 2024-03-19 | 安徽泽升科技股份有限公司 | 一种二氯甲烷的纯化方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN201364826Y (zh) | 2008-12-24 | 2009-12-16 | 比亚迪股份有限公司 | 紧急断电开关 |
WO2013030735A1 (en) | 2011-08-30 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
WO2013149121A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
WO2015110963A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | 2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents |
WO2015150890A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester |
WO2015159265A1 (en) | 2014-04-18 | 2015-10-22 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
WO2015173663A1 (en) | 2014-05-14 | 2015-11-19 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-[5-(2-methylamino-ethyl)-[1,3,4]-oxadiazol-2-yl]-7-oxo-1,6-diaza-bicyclo [3.2.1]oct-6-yl} ester |
WO2015173665A1 (en) | 2014-05-14 | 2015-11-19 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-[5-(3-azetidinylamino)-methyl-[1,3,4]- oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1] oct-6-yl} ester trifluoroacetate |
WO2017055922A1 (en) | 2015-10-02 | 2017-04-06 | Legochem Biosciences, Inc. | Compositions and methods for inhibiting beta-lactamase |
WO2019144912A1 (zh) | 2018-01-25 | 2019-08-01 | 苏州信诺维医药科技有限公司 | β-内酰胺酶抑制剂及其用途 |
-
2022
- 2022-11-17 WO PCT/CN2022/132591 patent/WO2023088375A1/zh active Application Filing
- 2022-11-17 CA CA3238268A patent/CA3238268A1/en active Pending
- 2022-11-17 AU AU2022393742A patent/AU2022393742A1/en active Pending
- 2022-11-17 CN CN202280076434.2A patent/CN118215665A/zh active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN201364826Y (zh) | 2008-12-24 | 2009-12-16 | 比亚迪股份有限公司 | 紧急断电开关 |
WO2013030735A1 (en) | 2011-08-30 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
WO2013149121A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
US20130296290A1 (en) | 2012-03-30 | 2013-11-07 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
WO2015110963A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | 2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents |
WO2015150890A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester |
WO2015159265A1 (en) | 2014-04-18 | 2015-10-22 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
WO2015173663A1 (en) | 2014-05-14 | 2015-11-19 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-[5-(2-methylamino-ethyl)-[1,3,4]-oxadiazol-2-yl]-7-oxo-1,6-diaza-bicyclo [3.2.1]oct-6-yl} ester |
WO2015173665A1 (en) | 2014-05-14 | 2015-11-19 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-[5-(3-azetidinylamino)-methyl-[1,3,4]- oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1] oct-6-yl} ester trifluoroacetate |
WO2017055922A1 (en) | 2015-10-02 | 2017-04-06 | Legochem Biosciences, Inc. | Compositions and methods for inhibiting beta-lactamase |
WO2019144912A1 (zh) | 2018-01-25 | 2019-08-01 | 苏州信诺维医药科技有限公司 | β-内酰胺酶抑制剂及其用途 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117720106A (zh) * | 2023-12-28 | 2024-03-19 | 安徽泽升科技股份有限公司 | 一种二氯甲烷的纯化方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2022393742A1 (en) | 2024-06-06 |
CN118215665A (zh) | 2024-06-18 |
CA3238268A1 (en) | 2023-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105916861B (zh) | 可用于合成软海绵素b类似物的方法 | |
CN1139596C (zh) | 头孢地尼的胺盐晶体 | |
WO2023088375A1 (zh) | β-内酰胺酶抑制剂中间体及制备方法 | |
CN104703992A (zh) | 噻吩并吡啶衍生物的制备方法 | |
EP3828170A1 (en) | Method for safely preparing pimavanserin and tartrate salt thereof using triphosgene | |
AU2004272255A1 (en) | Method for the production of 4-(4-aminophenyl)-3-morpholinon | |
CN109503628A (zh) | 一种他唑巴坦手性异构体的合成方法 | |
CA2664052A1 (en) | An improved process for the preparation of temozolomide and analogs | |
IT201800005874A1 (it) | Processo per la preparazione di apalutamide | |
CN107759577B (zh) | Gs5816中间体、制备方法及应用 | |
CN105481856A (zh) | 一种帕利哌酮的制备方法 | |
WO2020088053A1 (zh) | 抗生素teixobactin及其类似物的合成路线 | |
WO2019163731A1 (ja) | オキサゾリジノン化合物の製造方法 | |
CN102911186B (zh) | 一种头孢唑肟钠的制备及精制方法 | |
CN105859747A (zh) | 一种适于工业化生产的盐酸头孢吡肟的制备方法 | |
US9434702B2 (en) | Method for preparing linezolid intermediate | |
CN103396373A (zh) | 地拉罗司的制备方法及其中间体化合物 | |
CN108395444B (zh) | 一种3-乙基头孢羟氨苄的制备方法 | |
CN101633626B (zh) | L-间氨基苯甘氨酸及其衍生物、制备方法和应用 | |
KR20240107154A (ko) | β-락타마제 억제제 중간체 및 이의 제조 방법 | |
CN108503586B (zh) | 制备托伐普坦中间体的方法 | |
WO2012070066A1 (en) | Process for the preparation of taurolidine and its intermediates thereof | |
CN111763222A (zh) | 用于制备依度沙班游离碱的中间体及其制备方法和应用 | |
CN108727410A (zh) | 一种羟甲基头孢妥仑匹酯的制备方法 | |
CN106146340B (zh) | 一种西他列汀中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22894906 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3238268 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022393742 Country of ref document: AU Ref document number: AU2022393742 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020247018824 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2022393742 Country of ref document: AU Date of ref document: 20221117 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022894906 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022894906 Country of ref document: EP Effective date: 20240617 |